Use cases
Esophageal PDO—not KYSE / OE33 spheroids and not a full Barrett-only expansion course.
| Use | Fit | Readout | Notes |
|---|---|---|---|
| EAC biopsy / resection PDO biobank + drugs | Recommended | Genomic fidelity, clonal evolution, and drugs[1][2] | Li / Derouet etc. show EAC organoids recapitulate primary heterogeneity and support drugs. |
| ESCC PDO (squamous-optimized medium) | Contrast | Squamous markers / drugs | Separate dishes and media from EAC—do not mix banks[[3]]. |
| Calling Barrett expansion an EAC PDO | Do not mix | False-positive “tumor” drug reads | Barrett can contaminate cultures—confirm morphology / genomics before tumor claims[[2]]. |
In one line
Esophageal-tumor clusters → dome → Wnt/EGF niche (EAC vs ESCC media) → brief Y-27632 → mechanical split → CK/p53 → drugs.
Protocol overview
- Ethics + cold chain; log histology (EAC / ESCC), stage, and Barrett history
- Trim necrosis from biopsy/resection; collagenase ± Dispase to clusters; brief RBC lysis (MC427) if bloody
- Matrix domes; pick EAC- or ESCC-optimized medium (Wnt/Rspo/Noggin/EGF/FGF ± gastrin…)[[1]][[3]]
- Brief Y-27632; score cystic vs solid growth
- Feed every 2–3 days; mechanical split; if Barrett contamination suspected, split dishes and check morphology / genomics[[2]]
- CK7/CK20, EpCAM, p53 by study; mycoplasma; match the primary
- Drugs with vehicle and standard arms; in vivo uses transplant SOPs—not this page